{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:13:13Z","timestamp":1762639993400,"version":"3.41.2"},"reference-count":16,"publisher":"FapUNIFESP (SciELO)","issue":"6","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. bras. pneumol."],"abstract":"<jats:p>ABSTRACT  Objective: To describe the incidence of active tuberculosis and the occurrence of adverse events after isoniazid treatment in patients with latent tuberculosis infection (LTBI) who also had chronic inflammatory diseases and were treated with immunobiologic agents in an endemic area in Brazil.  Methods: The diagnosis of LTBI was based on anamnesis, clinical examination, chest X-ray, and a tuberculin skin test (TST). Patients received prophylactic treatment (isoniazid for six months) in accordance with the Brazilian guidelines.  Results: A total of 101 patients were evaluated between July of 2011 and July of 2015. Of those, 55 (54.46%) were women (mean age, 53.16 \u00b1 1.76 years) and 46 (45.54%) were men (mean age, 45.39 \u00b1 2.13 years). A total of 79 patients (78.22%) were being treated with immunobiologic agents and 22 (21.78%) were being treated with immunomodulatory or immunosuppressive agents. In the screening for LTBI, 53 patients (52.48%) had a TST induration \u2265 10 mm. Chest X-ray findings consistent with LTBI were observed in 36 patients (35.64%). Isoniazid preventive therapy was effective in 96 (95.05%) of the 101 patients evaluated. It is of note that 84 (83.17%) of the patients experienced no adverse effects from the use of isoniazid and that 83 (98.81%) of those patients completed the prophylactic treatment (p = 0.002). Active tuberculosis was diagnosed in 5 (6.33%) of the 79 patients treated with immunobiologic agents and in 1 (4.55%) of the 22 patients treated with other immunomodulators\/immunosuppressants.  Conclusions: A six-month course of isoniazid proved to be safe and effective in the treatment of LTBI, which is essential to reducing the risk of developing active tuberculosis.<\/jats:p>","DOI":"10.1590\/1806-3713\/e20180225","type":"journal-article","created":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T19:39:35Z","timestamp":1570909175000},"source":"Crossref","is-referenced-by-count":5,"title":["Diagnosis and treatment of latent tuberculosis infection in patients undergoing treatment with immunobiologic agents: a four-year experience in an endemic area"],"prefix":"10.1590","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-1023","authenticated-orcid":false,"given":"Diana Maria de Almeida","family":"Lopes","sequence":"first","affiliation":[{"name":"Universidade Federal do Cear\u00e1,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9745-824X","authenticated-orcid":false,"given":"Val\u00e9ria Goes Ferreira","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8525-9657","authenticated-orcid":false,"given":"Helena Serra Azul","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2019]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bjid.2015.12.003","article-title":"High incidence of tuberculosis in patients treated for hepatitis C chronic infection","volume":"20","author":"De Oliveira Uehara SN","year":"2016","journal-title":"Braz J infect Dis"},{"year":"2017","key":"ref2"},{"issue":"8","key":"ref3","first-page":"1","article-title":"Indicadores priorit\u00e1rios para o monitoramento do Plano Nacional pelo Fim da Tuberculose como Problema de Sa\u00fade P\u00fablica no Brasil","volume":"48","year":"2017","journal-title":"Bol Epidemiol"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4046\/trd.2014.76.6.261","article-title":"Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy","volume":"76","author":"Shim TS","year":"2014","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.5588\/ijtld.13.0755","article-title":"Screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area","volume":"18","author":"Bonfiglioli KR","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"ref6","first-page":"1018","article-title":"III Brazilian Thoracic Association Guidelines on tuberculosis","volume":"35","author":"Conde MB","year":"2009","journal-title":"J Bras Pneumol"},{"year":"2011","series-title":"Manual de Recomenda\u00e7\u00f5es para o Controle da Tuberculose no Brasil. S\u00e9rie A. Normas e Manuais T\u00e9cnicos","key":"ref7"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/s41598-017-06899-1","article-title":"Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection","volume":"7","author":"Lee EH","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4046\/trd.2017.0052","article-title":"Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy","volume":"81","author":"Kim HW","year":"2018","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"ref10","first-page":"PA2969","article-title":"Anti-TNF-alpha therapy in patients with latent tuberculosis incidence","volume":"46","author":"l Coskunol","year":"2015","journal-title":"Eur Respir J"},{"issue":"15","key":"ref11","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane J","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1590\/S0482-50042011000200005","article-title":"Brazilian biologic registry BiobadaBrasil implementation process and preliminary results","volume":"51","author":"Titton DC","year":"2011","journal-title":"Rev Bras Reumatol"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1513\/AnnalsATS.201608-647OC","article-title":"Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist","volume":"14","author":"Lee J","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"ref14","first-page":"809","article-title":"Latent tuberculosis infection treatment Current recommendations","volume":"16","author":"Duarte R","year":"2010","journal-title":"Rev Port Pneumol"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1579-2129(08)60086-5","article-title":"Effectiveness and tolerance of antituberculosis treatment regimens without isoniazid and rifampicin analysis of 85 cases","volume":"44","author":"Tost JR","year":"2008","journal-title":"Bronconeumol"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1590\/S0074-02762009000300011","article-title":"Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro","volume":"104","author":"Souza CT","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/jbpneu\/v45n6\/1806-3713-jbpneu-45-06-e20180225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T21:27:18Z","timestamp":1581456438000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1806-37132019000600207&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019]]}},"alternative-id":["S1806-37132019000600207"],"URL":"https:\/\/doi.org\/10.1590\/1806-3713\/e20180225","relation":{},"ISSN":["1806-3756","1806-3713"],"issn-type":[{"type":"electronic","value":"1806-3756"},{"type":"print","value":"1806-3713"}],"subject":[],"published":{"date-parts":[[2019]]},"article-number":"e20180225"}}